Johnson & Johnson (NYSE:JNJ) Trading Down 1% – Time to Sell?

Shares of Johnson & Johnson (NYSE:JNJ) fell 1% during trading on Tuesday . The company traded as low as $236.01 and last traded at $238.4710. 6,226,954 shares were traded during trading, a decline of 29% from the average session volume of 8,721,360 shares. The stock had previously closed at $240.97.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Citigroup raised its price target on JNJ to $285 and kept a “buy” rating, signaling strong analyst conviction and a sizeable implied upside. Citigroup adjusts price target on Johnson & Johnson to 285 from 274; maintains buy rating
• Positive Sentiment: Guggenheim also nudged up its target to $244 and maintained a “buy” rating, providing additional analyst support (smaller upside than Citigroup but still positive). Guggenheim adjusts price target on Johnson & Johnson to 244 from 240; maintains buy rating
• Positive Sentiment: Regulatory and clinical wins: J&J secured a permanent U.S. reimbursement code for bladder‑cancer therapy INLEXZO, reported 52‑week efficacy for oral peptide ICOTYDE in plaque psoriasis, and struck an exclusive Japan distribution deal for SIRTURO — all improve specialty‑therapy revenue visibility. Johnson & Johnson Updates Key Specialty Therapies And Undervaluation Signals For Investors
• Positive Sentiment: Medtech product launch: J&J received CE Mark clearance and is introducing VARIPULSE Pro / next‑gen Varipulse PFA catheter in Europe — a commercial catalyst for the cardiovascular devices franchise. Johnson & Johnson brings next-gen Varipulse PFA catheter to Europe Johnson & Johnson introduces VARIPULSE Pro in Europe after CE Mark clearance
• Positive Sentiment: Technical/market interest: Market commentary notes JNJ is in or near a buy zone, which could attract momentum/technical buyers if conditions align. Dow Jones Medical Giant Johnson & Johnson Eyes Latest Buy Point
• Positive Sentiment: Analyst consensus remains constructive — a “Moderate Buy” consensus was reported, reinforcing that the analyst community sees upside versus current levels. Johnson & Johnson (NYSE:JNJ) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Sector comparison piece contrasts J&J with Coca‑Cola on “reliability” and income characteristics — useful for allocation decisions but not an immediate stock catalyst. $10,000 to Invest? Coca-Cola or Johnson & Johnson- One Stock Is More Reliable

Analyst Upgrades and Downgrades

A number of research firms have recently commented on JNJ. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Loop Capital set a $220.00 target price on shares of Johnson & Johnson in a research note on Tuesday, January 27th. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Finally, Argus boosted their price target on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $237.57.

Johnson & Johnson Stock Down 1.0%

The stock has a market capitalization of $574.38 billion, a price-to-earnings ratio of 21.58, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34. The business’s 50-day moving average is $240.25 and its two-hundred day moving average is $213.73. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,142 shares of company stock worth $7,360,528 over the last 90 days. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Johnson & Johnson

Hedge funds have recently made changes to their positions in the company. Blueline Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $25,000. Abich Financial Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $26,000. Cresta Advisors Ltd. acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $26,000. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $27,000. Finally, Clayton Financial Group LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $28,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.